Airway transcriptomic signatures

Summary

The abstract of the review by Burman and colleagues names this candidate biomarker (gene-expression patterns measured in airway samples). The abstract states that the biomarkers named may aid risk stratification, patient enrichment and endotype-guided trials. No performance data are stated, and this record is a stub that is unverified beyond the abstract. Only the abstract of the source review was read; the full text was not read.

Sources and links

• Burman et al. 2026, J Heart Lung Transplant (DOI; abstract only was read) (primary)
• PubMed record (PMID 42854767)

Related

Links from this record

• named in (abstract only): CLAD: translating basic science to clinical practice
• candidate for endotype-guided use: Molecular endotypes of CLAD (proposed framework)

Linked from (derived)

• related to: Transbronchial biopsy: histology and transcript-based classifiers
• related to: A transcriptomic atlas of chronic lung allograft dysfunction.
• evidence for: Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways
• related to: Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression
• related to: Single-cell dissection of chronic lung allograft dysfunction reveals convergent and distinct fibrotic mechanisms
• affects: Definitions and prognosis of ALAD and BLAD are not settled
• affects: CLAD is recognised late and no biomarker is validated for early warning
• affects: No validated molecular endotype scheme exists for CLAD

Known gaps in this record

• full text of the source review not read, so the evidence, citations and level of agreement for this item are missing
• funding and conflicts of interest of the source review not read
• assay, performance and validation status not recorded